Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy

Volume: 378, Issue: 7, Pages: 625 - 635
Published: Feb 14, 2018
Abstract
Background Nusinersen is an antisense oligonucleotide drug that modulates pre–messenger RNA splicing of the survival motor neuron 2 (SMN2) gene. It has been developed for the treatment of spinal muscular atrophy (SMA). Methods We conducted a multicenter, double-blind, sham-controlled, phase 3 trial of nusinersen in 126 children with SMA who had symptom onset after 6 months of age. The children were randomly assigned, in a 2:1 ratio, to undergo...
Paper Details
Title
Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy
Published Date
Feb 14, 2018
Volume
378
Issue
7
Pages
625 - 635
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.